POINT Biopharma Global Inc.
POINT Biopharma Global Inc. (PNT): 28 pipeline candidates · ~35 mo cash runway · 28 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
34.9 months
0% dilution
Lead: Phase 3
28 candidates
N/A
N/A
A transparent, data-derived signal for POINT Biopharma Global Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$21.6M
Quarterly Burn
$28.1M
Runway
34.9 mo
Revenue
$2.8M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (28 candidates)
| Drug | Phase |
|---|---|
| 177lu-pnt2002 | Phase 3 |
| 177lu-pnt2003 | Phase 3 |
| 177lu-pnt6555 | Phase 1 |
| 225ac-psma-62 | Preclinical |
| ahb-137 | Phase 1 |
| ahb-171 | Phase 1 |
| anti-cd20 antibodies | Phase 3 |
| bimekizumab | Phase 2 |
| cbp-4888 | Early Phase 1 |
| dapirolizumab pegol | Phase 3 |
Showing 10 of 28 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in POINT Biopharma Global Inc.'s pipeline?
POINT Biopharma Global Inc. (PNT) has 28 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is POINT Biopharma Global Inc.'s lead drug candidate?
POINT Biopharma Global Inc.'s most advanced tracked candidate is 177lu-pnt2002 (Phase 3) for metastatic castration-resistant prostate cancer (mCRPC).
What is POINT Biopharma Global Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, POINT Biopharma Global Inc. has approximately 34.9 months of cash runway.
Who is the CEO of POINT Biopharma Global Inc.?
Joe Mc is the chief executive officer of POINT Biopharma Global Inc. (PNT).
Get the full picture on POINT Biopharma Global Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.